Hongxia Sun

Hongxia Sun

Auto-generated profile, based on publicly available information

Hongxia Sun

Department of Pathology The University of Texas MD Anderson Cancer Center Houston Texas USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2018 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
HSHongxia Sun
Hongxia Sun
RMRamya P. Masand
Ramya P. Masand
SPShobhanaben Jagdishbhai Patel
Shobhanaben Jagdishbhai Patel
VPVijayalakshmi Padmanabhan
Vijayalakshmi Padmanabhan

1 April 2021 in European Journal of Breast Health
Verified
Journal Article
Closed access
HSHongxia Sun
Hongxia Sun
HCHui Chen
Hui Chen
JCJames Crespo
James Crespo
GTGuilin Tang
Guilin Tang
MRMelissa Robinson
Melissa Robinson
AŞAyşegül A. Şahin
Ayşegül A. Şahin
The interpretation of human epidermal growth factor receptor 2 (HER2) fluorescence in situ hybridization (FISH) results may be challenging in tumors with polysomy 17, which is defined as increased signals of chromosome enumeration probe 17 (CEP17). The effect of polysomy 17 on HER2 protein expression and tumor treatment response has not been established. In this retrospective study, we investigated the clinicopathological features of breast cancer with polysomy 17 and determined the tumors’ response to neoadjuvant chemotherapy (NACT). The study included 366 patients with primary breast cancer whose tumors had a CEP17 count of ≥ three/nucleus based on HER2 FISH studies. These cases were categorized according to HER2/CEP17 ratio and HER2 signals/nucleus using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. We compared the clinicopathological characteristics and tumor response to NACT among different groups. There was a statistically significant difference in patients’ age at diagnosis, tumor pathological grade, estrogen and progesterone receptor status, and NACT response among different HER2 FISH groups. Polysomy 17 tumors in group 1 had a higher rate of response (pathological complete response and residual cancer burden class I) to NACT containing anti-HER2 reagent than did those in other groups (p = 0.004), whereas polysomy 17 tumors in group 3 did not show a significant response to anti-HER2 treatment. Polysomy 17 tumors in different HER2 FISH groups have different pathological features and respond to NACT differently. These results may help us identify patients who will benefit from anti-HER2 therapy.

5 March 2024 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
HSHongxia Sun
Hongxia Sun
EKEun Young Kang
Eun Young Kang
HCHui Chen
Hui Chen
KSKeith Sweeney
Keith Sweeney
MSMichael Suchko
Michael Suchko
ASAysegul A. Sahin
Aysegul A. Sahin

30 September 2025 in Histopathology
Verified
Journal Article
Closed access
QYQiqi Ye
Qiqi Ye
JEJeannelyn Estrella
Jeannelyn Estrella
NKNeda Kalhor
Neda Kalhor
ALAudrey Liu
Audrey Liu
CHCody Han
Cody Han
QDQingqing Ding
Qingqing Ding